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the operating principles and protocols for collection, retention,
retrieval, and analysis of demographic information, signs and
symptoms—including laboratory ﬁndings—and the response to
enzyme replacement therapy with agalsidase alfa in patients with
a conﬁrmed diagnosis of Fabry disease. RESULTS: As of Decem-
ber 2007, 190 centres have enrolled 1453 patients from 19
countries worldwide (754 females, 699 males). Of these, 133 are
girls and 118 boys less than 18 years of age. Data from these
patients have added signiﬁcantly to our understanding of Fabry
disease, with 24 peer-reviewed publications describing the pre-
treatment characteristics of the disease and the response to
agalsidase alfa. Problems encountered include: 1) incomplete
ascertainment of patients with different manifestations of Fabry
disease; 2) some systematic lacunae in the data; and 3) uncer-
tainty about the quality of some data. Progress has been made in
overcoming these problems by: 1) convening regular meetings of
investigators to review protocols, data collection, and ﬁndings
from data analysis; 2) focusing on ‘core data’; 3) concentrating
on achieving comprehensive data collection from centres where
enrolment is especially high; and 4) employing clinical research
associates to increase data collection and ensure data quality.
CONCLUSIONS: FOS has contributed signiﬁcantly to the
understanding of the clinical features of Fabry disease in patients
of all ages. Problems with data collection and quality have been
addressed by a multi-faceted approach, including focusing on a
core panel of data to be collected, together with the use of clinical
research associates to check data completeness and quality.
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OBJECTIVE: Over the past decade, there has been a tremendous
increase in the prevalence of autism spectrum disorders (ASD) in
the United States. With increasing ASD prevalence, the health
care utilization and costs associated with these neurodevelop-
mental disabilities are also expected to increase. The purpose of
this study is to determine the trends in the prevalence of ASD and
ASD-related health care utilization and costs among recipients
enrolled in a state Medicaid program. METHODS: A retrospec-
tive descriptive analysis of a state Medicaid fee-for-service
administrative claims dataset was conducted. Medical services
claims with a primary, secondary, or tertiary diagnosis code of
ASD (ICD-9-CM 299.0/299.8) were extracted to determine the
prevalence of ASD. Claims for psychotropic medications
prescribed to recipients with ASD were then extracted using
de-identiﬁed unique recipient numbers obtained from the
medical services claims. Prevalence and health care utilization
numbers and rates were reported by demographic categories.
Costs were reported from the state Medicaid perspective.
RESULTS: Between 1996 and 2003, the number of recipients
identiﬁed with ASD increased from 246 to 1399, respectively. In
terms of age distribution, recipients in the age group 6–14 years
represented the highest proportion in all the study years, with the
proportion increasing from 38.6% in 1996 to 47.0% in 2003. A
majority of the recipients with ASD were males, who made
69.1% of the sample in 1996 and 74.6% in 2003. Whites con-
stituted a majority (>90%) with respect to ethnicity in all the
study years. The increase in the prevalence of ASD was accom-
panied by an increase in ASD-related health care utilization and
costs. CONCLUSION: Similar to national trends, the prevalence
of ASD increased considerably over the years in the state Med-
icaid program. In addition, the prevalence of ASD among Med-
icaid recipients varied by demographic characteristics. The study
provides useful data to better serve the needs of this growing
population.
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OBJECTIVES: Few studies have evaluated trends among inpa-
tients with cystic ﬁbrosis. The purpose of this paper is to explore
patient demographics, diagnosis, and procedures to gather a
general picture of cystic ﬁbrosis treatment. Exploration of the
cystic ﬁbrosis data set to ﬁnd trends among the variables, race,
gender, mortality, total charges, length of stay, age diagnosis, and
procedures provides insight into better methods to treat indi-
viduals with cystic ﬁbrosis. METHODS: The data used were
taken from the National Inpatient Sample (NIS). The cystic
ﬁbrosis data set was formed by isolating the NIS patients diag-
nosed with cystic ﬁbrosis, using a 10% sample from 2004. The
cystic ﬁbrosis data set contained 1582 observations. Descriptive
statistics were used to examine the data; chi-square tests and
logistic regressions were employed to analyze the data.
RESULTS: Statistics showed that patients with a longer length of
stay were more likely to die during hospitalization and to be
older. Most races had two high density ages; one around 20
years of age and the other around 60 years of age with the
exception of African Americans and Native Americans. The
three procedures: transfusion of packed cells (ICD-9 99.04),
continuous ventilation <96 consecutive hours (ICD-9 96.71),
and endotracheal tube insertion (ICD-9 96.04) and two diag-
noses pneumonia (ICD-9 486) and amyloidosis (ICD-9 277.3,
accumulate deposits of abnormal proteins) were found to be
directly related to mortality. The data also showed that none of
the patients with esophageal reﬂux (ICD-9 530.81) died during
hospitalization. CONCLUSIONS: From the results, older
patients, patients with long lengths of stay, or those diagnosed
with amyloidosis could be considered high-risk for hospital mor-
tality. However, these results are limited; no information about
outpatient factors, medications, or test results could be assessed.
Also, there were few patients who died during hospitalization on
which to base the analysis.
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OBJECTIVE: To assess the rate of substance abuse among
insomnia patients prescribed nonbenzodiazepine receptor
agonists (nBZRAs), benzodiazepines (BZDs), and melatonin
receptor agonists (MRAs). METHODS: This analysis used a
retrospective matched cohort design with data from Florida
Medicaid recipients 18 to 64 years old. Patients initiating
nBZRA, BZD, or MRA therapy between July 1, 2002 and March
31, 2006, without a history of substance abuse, were included in
this analysis. One MRA patient was matched to three nBZRA
and three BZD patients based n demographic and clinical
(history of insomnia, depression, anxiety) characteristics. Service
dates and days of medication supply variables from pharmacy
claims established periods of treatment exposure, while sub-
stance abuse related to sedatives and hypnotics was identiﬁed
using International Classiﬁcation of Diseases 9th edition Clinical
Modiﬁcation (ICD-9-CM) codes for the same time frame. Rates
of substance abuse (SA) were calculated as the number of
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patients with a claim for SA per 100 patient-years of treatment
exposure. RESULTS: A total of 140 MRA patients were identi-
ﬁed and matched to 420 nBZRA and 420 BZD patients by age
(mean 46 years), sex (64% female), race (57% white), depression
(50%), and anxiety (14%). The mean Charlson co-morbidity
score was higher for MRA patients (1.4) than nBZRA or BZD
patients (0.6 and 0.7, respectively, P < 0.01). The SA rate per 100
patient-years of exposure was 1.84 and 2.51 for nBZRA and
BZD patients, respectively. There was no evidence of substance
abuse among the MRA cohort. CONCLUSION: These initial
data suggest that MRA patients were less likely to use medical
services for substance abuse than nBZRA or BZD patients.
However, given the small number of patients in this study, no
deﬁnitive conclusions can be drawn. Additional data will be
needed to conﬁrm these ﬁndings.
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OBJECTIVE: To estimate the potential impact of a ﬁxed-dose
combination of sumatriptan 85mg and naproxen sodium 500mg
(suma/nap) on triptan consumption in a United States managed
care population of moderate-to-severe adult migraineurs.
METHODS: A payer-perspective pharmacy budget impact
model was developed using Microsoft Excel®. Dose-speciﬁc
efﬁcacy was drawn from published meta-analyses for suma-
triptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, and
naratriptan, and derived from published trials for suma/nap.
Initial response rates at two hours, recurrence rates, and 24-hour
sustained pain free rates were used to model mean triptans con-
sumed per migraine episode. Nationally representative data for
market share and quantity dispensed from commercial sources as
well as prevalence data from the literature were combined with
modeled triptan consumption to estimate the number of total
annual prescriptions (TRx) ﬁlled. Probabilistic and scenario-
based sensitivity analyses were used to assess model uncertainty.
RESULTS: In a hypothetical plan of 1,000,000 covered lives, an
estimated 14,540 moderate-to-severe adult migraineurs treated
with currently available triptans ﬁlled 102,206 TRx. Of the 12
triptan doses evaluated, suma/nap had the lowest mean triptan
consumption per migraine episode (1.08; CI 1.06–1.09), fol-
lowed by naratriptan 2.5mg (1.10; CI 1.06–1.14), eletriptan
20mg (1.14; CI 1.09–1.19), and sumatriptan 25mg (1.15; CI
1.13–1.18). After converting 8.6% of TRx share (58.3% from
sumatriptan and 41.7% from other triptans according to market
share) to suma/nap, migraineurs ﬁlled only 100,356 TRx, a net
reduction of 1,850 prescriptions [CI 1,714–1,965]. In a second
scenario converting 8.6% of TRx share (100% from suma-
triptan), migraineurs ﬁlled 101,253 TRx, a net reduction of
953 prescriptions [CI 811–1,076]. CONCLUSION: Treating
a portion of moderate-to-severe migraineurs with suma/nap
reduced triptan consumption in a hypothetical nationally repre-
sentative managed care plan. Further research is required to
quantify the potential economic impact of this reduction once
suma/nap pricing is established.
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OBJECTIVE: To estimate the budget impact of switching from
Rivastigmine capsules to Rivastigmine Transdermal Adhesives in
Brazilian Public Health System. METHODS: A simulation model
from Public Health System perspective, with a time horizon of
three years was developed. In order to explore the minimum and
maximum possible budget impact, two scenarios were per-
formed. In the scenario A the patients are kept in the current
treatment dosage proﬁle using transdermal adhesive. In scenario
B the patients are successfully switched to higher doses using
transdermal adhesives as label and clinical studies recommenda-
tions. The capsules formulations analyzed were: 1.5 mg; 3 mg;
4.5 mg e 6 mg. The transdermal formulations evaluated were
5 cm2 and 10 cm2. The indication of target dose of 10 cm2
rivastigmine transdermal adhesives provides efﬁcacy similar to
the highest doses of capsules was based on clinical and pharma-
cological trials. Data from medication unit’s dispensation were
collected from public health database, ranging from October
2004 to September 2007. Cost information was collected from
ofﬁcial reimbursement list. The rate of switching from capsules to
transdermal adhesives was based on randomized controlled trial
related to caregiver preference. Results were converted in US
Dollars (R$ 1,8/USD 1.00). A one-way sensitivity analysis was
performed. RESULTS: In scenario A it was estimated that the
government could obtain a reduction of USD$2.7 million, or
6.02% of expenses. A reduction of 37% of pharmacy dispensa-
tion activities was associated with lowest health service resource
utilization. On the other hand in scenario B government expenses
are 6.36% higher (USD$3.2 million) but with reduction of 31%
of pharmacy dispensation activities. All scenarios are sensible
to transdermal adhesives costs. CONCLUSION: Rivastigmine
transdermal adhesives would be advantageous to Brazilian Public
Health System providing budget savings with lower resource
utilization. Although higher dosage of medication increases
expenses, pharmacy dispensation activities would be lower.
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OBJECTIVE: To compare medical costs among switching, dis-
continuing and persisting patients on multiple sclerosis (MS)
treatment. METHODS: Using the PharMetrics medical claims
database, adults diagnosed with MS who initiated treatment with
interferon beta (A-Avonex, B-Betaseron, R-Rebif) or glatiramer
acetate (C-Copaxone) in 1996–2005 were identiﬁed. Within each
drug initiator group, patients who persisted with the index treat-
ment, switched drugs, and discontinued MS medications, during
the ﬁrst 18 months after drug start were identiﬁed. Total medical
costs for the 18 months following treatment switch or discon-
tinuation, and for a randomly selected 18-month period among
those who persisted, were compared using multivariate linear
regression models. RESULTS: Among 6073 patients who initi-
ated treatment, the mean age was 43 years, 78% were female,
and 16% had treatment with a different MS drug prior to index
drug start. At 18 months after start of the index drug, 3365
(55%) of patients persisted; 685 (11%) switched, and 2023
(33%) of patients discontinued treatment for at least 90 days.
Mean medical costs over 18 months were $10,718, $8,786, and
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